Company news
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) news
Every Insight Molecular Diagnostics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
September 2, 2026
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
August 10, 2026
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
August 4, 2026
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
July 23, 2026
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
June 29, 2026
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
June 22, 2026
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
June 16, 2026
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
June 11, 2026
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
June 9, 2026
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
May 13, 2026
iMDx to Release First Quarter 2026 Results on May 13, 2026
May 6, 2026
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
March 26, 2026
IMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
March 23, 2026
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
March 20, 2026
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
March 13, 2026
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
March 3, 2026
iMDx Announces $26.0 Million Registered Direct Offering
February 11, 2026
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
January 13, 2026
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
January 7, 2026
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch
January 6, 2026
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion
January 5, 2026
Insight Molecular Diagnostics : TitleNominating and Corporate Governance Charter
December 18, 2025
Insight Molecular Diagnostics : TitleCompensation Committee Charter
December 18, 2025
Insight Molecular Diagnostics : TitleAudit Committee Charter
December 18, 2025
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch
November 10, 2025
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
November 3, 2025
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
October 13, 2025
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
October 6, 2025
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
September 24, 2025
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
September 8, 2025
IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
September 8, 2025
iMDx to Participate in NYC Investment Conferences September 8 - 11
August 26, 2025
IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics
August 25, 2025
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
August 11, 2025
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
August 4, 2025
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients
July 30, 2025
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025
July 28, 2025
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
June 23, 2025
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
June 17, 2025